NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Sentiment, Thanks for bringing up the history and risk with Yorkville. Overall, I think the Dec 2024 Yorkville financing deal w/ NWBO is fine, but it is also a good exercise to assess the risk of “death-spiral financing”. TLDR: I think LP negotiated sufficient safeguards into the deal.

Yorkville has used its traditional standby equity purchase deal model. These deals involve buying shares at a discount and selling them back when the company needs cash. A Wall Street veteran described this approach bluntly: “People used to call it death-spiral financing.”

My thoughts, with some help from AI research.

Yorkville's $50M equity standby facility:
- Mechanism for manipulation requires 2 features: 1) a discounted-to-mkt price and 2) lender controls timing. (Enables scenario: lender shorts stock in advance, to lower price to get more stock/dilution, which pushes price down. Rinse and repeat to create a death-spiral.)
- Discounted price: Yes, "at a small discount to the then market price”
- Lender controls timing: No, NWBO controls, at their option and discretion, if and when to use.
- Therefore, NWBO effectively neutered that mechanism.

Yorkville's $5M convertible note:
- Standard dilutive financing, but has concerning features (discount price and lender controls timing for conversion)
- Protective/mitigating term: "The amounts of such conversions are limited to one sixth (1/6) of the overall Note amount in any given calendar month unless the conversion price is above $0.315."
- Therefore, NWBO put in a mitigating guardrail, slows the rate and potential impact

The Oct 2025 Streeterville debt financing is much cleaner. It uses traditional interest (discounts/fees) and has no dilutive items like conversions or warrants. Maybe that is why a year later, NWBO switched to Streeterville, and it is important to have clean balance sheet items as the company grows.